OptimizeRx (NASDAQ:OPRX) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

OptimizeRx (NASDAQ:OPRX) released its quarterly earnings results on Wednesday. The company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.03), Zacks reports. OptimizeRx had a return on equity of 9.44% and a net margin of 4.66%.

OptimizeRx Stock Performance

Shares of NASDAQ:OPRX traded down $0.40 on Wednesday, hitting $8.95. The company’s stock had a trading volume of 365,145 shares, compared to its average volume of 350,150. The company has a market capitalization of $168.58 million, a price-to-earnings ratio of 38.91 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.58 and a current ratio of 5.58. OptimizeRx has a 12 month low of $4.54 and a 12 month high of $16.37. The stock’s 50-day moving average is $8.40 and its two-hundred day moving average is $7.25.

Analyst Ratings Changes

Several analysts recently weighed in on OPRX shares. Weiss Ratings upgraded shares of OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, August 25th. Citigroup restated a “market outperform” rating on shares of OptimizeRx in a research report on Tuesday, October 27th. Stifel Nicolaus set a $12.00 target price on shares of OptimizeRx in a research report on Thursday, August 13th. Wall Street Zen lowered shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. Finally, UBS Group set a $11.00 price target on OptimizeRx in a report on Friday, August 14th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.57.

OptimizeRx Company Profile

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey. The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.